Tempus AI (NASDAQ:TEM) Given “Buy” Rating at Needham & Company LLC

Tempus AI (NASDAQ:TEM)‘s stock had its “buy” rating reissued by Needham & Company LLC in a report released on Friday,Benzinga reports. They currently have a $75.00 price objective on the stock. Needham & Company LLC’s price target would indicate a potential upside of 69.34% from the company’s previous close.

A number of other analysts also recently weighed in on TEM. Guggenheim increased their price target on shares of Tempus AI from $60.00 to $65.00 and gave the company a “buy” rating in a report on Thursday, July 16th. Lake Street Capital downgraded Tempus AI to a “hold” rating in a report on Monday, July 20th. BTIG Research restated a “buy” rating and set a $80.00 target price on shares of Tempus AI in a research report on Monday, June 1st. Weiss Ratings reiterated a “sell (e+)” rating on shares of Tempus AI in a research note on Wednesday, June 17th. Finally, TD Cowen restated a “buy” rating on shares of Tempus AI in a research note on Wednesday, July 15th. Nine equities research analysts have rated the stock with a Buy rating, five have given a Hold rating and two have assigned a Sell rating to the stock. According to data from MarketBeat.com, the stock currently has a consensus rating of “Hold” and an average price target of $68.92.

Tempus AI Price Performance

NASDAQ TEM opened at $44.29 on Friday. The stock has a 50-day simple moving average of $51.45 and a 200 day simple moving average of $52.77. Tempus AI has a twelve month low of $40.77 and a twelve month high of $104.32. The stock has a market capitalization of $7.95 billion, a PE ratio of -25.75 and a beta of 3.46. The company has a debt-to-equity ratio of 2.96, a quick ratio of 3.15 and a current ratio of 3.31.

Tempus AI (NASDAQ:TEM) last issued its quarterly earnings results on Thursday, July 30th. The company reported ($0.04) EPS for the quarter, topping the consensus estimate of ($0.14) by $0.10. Tempus AI had a negative return on equity of 53.83% and a negative net margin of 22.20%.The company had revenue of $382.49 million for the quarter, compared to the consensus estimate of $379.69 million. During the same period in the previous year, the business posted ($0.22) EPS. The company’s revenue for the quarter was up 21.6% on a year-over-year basis. Research analysts anticipate that Tempus AI will post -1.35 EPS for the current year.

Insider Buying and Selling

In related news, CAO Ryan M. Bartolucci sold 4,116 shares of Tempus AI stock in a transaction dated Tuesday, May 19th. The stock was sold at an average price of $44.07, for a total value of $181,392.12. Following the completion of the transaction, the chief accounting officer directly owned 74,041 shares of the company’s stock, valued at $3,262,986.87. The trade was a 5.27% decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is available through the SEC website. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Also, CEO Eric P. Lefkofsky sold 250,000 shares of the company’s stock in a transaction dated Tuesday, July 28th. The stock was sold at an average price of $42.06, for a total transaction of $10,515,000.00. Following the transaction, the chief executive officer owned 200,000 shares in the company, valued at approximately $8,412,000. This trade represents a 55.56% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders sold a total of 699,793 shares of company stock valued at $33,763,231 in the last 90 days. 24.26% of the stock is owned by corporate insiders.

Hedge Funds Weigh In On Tempus AI

Hedge funds have recently added to or reduced their stakes in the company. Victory Capital Management Inc. boosted its position in shares of Tempus AI by 1.5% in the 3rd quarter. Victory Capital Management Inc. now owns 11,078 shares of the company’s stock worth $894,000 after purchasing an additional 162 shares during the last quarter. Legacy Bridge LLC lifted its stake in Tempus AI by 1.6% in the fourth quarter. Legacy Bridge LLC now owns 12,418 shares of the company’s stock valued at $733,000 after buying an additional 193 shares during the period. Truist Financial Corp lifted its stake in Tempus AI by 5.8% in the fourth quarter. Truist Financial Corp now owns 3,532 shares of the company’s stock valued at $209,000 after buying an additional 194 shares during the period. Farther Finance Advisors LLC boosted its holdings in Tempus AI by 3.5% during the fourth quarter. Farther Finance Advisors LLC now owns 6,390 shares of the company’s stock worth $377,000 after buying an additional 219 shares during the last quarter. Finally, SeaCrest Wealth Management LLC grew its position in shares of Tempus AI by 3.7% during the 3rd quarter. SeaCrest Wealth Management LLC now owns 6,488 shares of the company’s stock worth $524,000 after buying an additional 229 shares during the period. Institutional investors own 24.22% of the company’s stock.

Key Tempus AI News

Here are the key news stories impacting Tempus AI this week:

• Positive Sentiment: Q2 earnings beat expectations. Tempus reported an adjusted loss of $0.04 per share, narrower than the $0.14 consensus estimate and the $0.22 loss recorded a year earlier. Revenue rose 21.6% year over year to $382.49 million, slightly exceeding analysts’ $379.69 million forecast. Tempus AI Q2 earnings report
• Positive Sentiment: Diagnostics and AI initiatives are driving momentum. Management described strong growth in Oncology Diagnostics and other major businesses, citing investments in artificial intelligence, data and modeling capabilities as key contributors. The company also outlined potential long-term growth from its xT CDx and xF products, including a projected $400 million revenue uplift by 2028. Tempus Reports Second Quarter 2026 Results
• Neutral Sentiment: 2026 revenue guidance remains broadly in line with expectations. Tempus reaffirmed a full-year revenue outlook of approximately $1.595 billion to $1.605 billion, near the $1.6 billion analyst consensus. While the outlook supports continued expansion, it provides limited incremental upside versus current estimates. Tempus 2026 revenue guidance
• Negative Sentiment: CEO insider selling may weigh on sentiment. Chief Executive Officer Eric Lefkofsky sold 250,000 shares for approximately $10.5 million, reducing his direct ownership by 55.56% to 200,000 shares. The transaction was conducted under a pre-arranged Rule 10b5-1 plan, which reduces its significance as a discretionary signal, but the sizable sale could still concern investors. Eric Lefkofsky Tempus AI insider sale

About Tempus AI

Tempus is a technology-driven healthcare company that applies artificial intelligence and machine learning to clinical and molecular data in order to advance precision medicine. Its primary focus lies in oncology, where the company offers comprehensive genomic profiling, digital pathology services and data-driven insights to inform personalized cancer care. By integrating DNA and RNA sequencing with structured clinical information, Tempus enables clinicians and researchers to identify targeted treatment options for patients based on the genetic characteristics of their tumors.

The company’s core offering centers on a scalable, cloud-based analytics platform that aggregates vast amounts of molecular and clinical data.